The importance of characterization of FITC-labeled antibodies used in tissue cross-reactivity studies

Acta Histochemica

Volumn 113, Issue 4, 2011, Pages 472-476

  Takai, Hirotake ^a   Kato, Atsuhiko ^a   Nakamura, Teruo ^a   Tachibana, Tatsuhiko ^a   Sakurai, Takayuki ^a   Nanami, Masahiko ^a   Suzuki, Masami ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Binding affinity; FITC; Fluorescein isothiocyanate; Immunohistochemistry; Non specific staining; Tissue cross reactivity; Tocilizumab

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE; HUMAN MONOCLONAL ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; TOCILIZUMAB;

ANTIBODY LABELING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CORRELATION COEFFICIENT; CROSS REACTION; ENZYME IMMUNOASSAY; HUMAN; HUMAN TISSUE; IC 50; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; PROTEIN EXPRESSION;

AFFINITY LABELS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CROSS REACTIONS; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; ORGAN SPECIFICITY;

EID: 79953769560     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2010.04.007     Document Type: Article

References (16)

1. Atreya R., Mudter J., Finotto S., Müllberg J., Jostock T., Wirtz S., et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn's disease and experimental colitis in vivo. Nat Med 2000, 6:582-583.
2. Chan CM Monoclonal antibody tissue cross-reactivity studies: preclinical safety assessment of cross-reactive binding and selection of relevant animal species for toxicity testing. Tanimoto School-Questions of Toxicity 2007, vol. 10:66-79. Scientist Inc., Tokyo.
3. Finney D.J. Parallel line assays. Statistical method in biological assay 1978, Charles Griffin, Company Ltd., London, pp. 69-104. 3rd ed.
4. Fung K.M., Messing A., Lee V.M., Trojanowski J.Q. A novel modification of the avidin-biotin complex method for immunohistochemical studies of transgenic mice with murine monoclonal antibodies. J Histochem Cytochem 1992, 40:1319-1328.
5. Gary P.B. Fall Retreat focuses on nanotechnology, tissue cross-reactivity studies, guidances on National Formulary reference terminology, statistical consults for carcinogenicity studies, Pharm/Tox Web Page, Education Subcommittee updates. News Along the Pike 2006, 12:9-12.
6. Ito H. Anti-interleukin-6 therapy for Crohn's disease. Curr Pharm Des 2003, 9:295-305.
7. Kato A., Watanabe T., Yamazaki M., Deki T., Suzuki M. IL-6R distribution in normal human and cynomolgus monkey tissues. Regul Toxicol Pharm 2009, 53:46-51.
8. Liu X.Y., Pop L.M., Vitetta E.S. Engineering therapeutic monoclonal antibodies. Immunol Rev 2008, 222:9-27.
9. Nakura H., et al. High sensitive staining method. Watanabe-Nakano immunoenzymatic technique 2002, 136-162. Gakusaikikaku Co., Ltd., Tokyo. 4th ed. H. Nakura, Y. Nagamura, Y. Tsutsumi (Eds.).
10. Mihara M., Nishimoto N., Ohsugi Y. The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Exp Opin Biol Ther 2005, 5:683-690.
11. Ohsugi Y., Kishimoto T. The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. Exp Opin Biol Ther 2008, 8:669-681.
12. Polak J.M., Van Noorden S. Introduction to immunocytochemistry 1997, Bios Scientific Publishers Ltd., Oxford, UK, pp. 50-4. 3rd ed.
13. Poli M.A., Rivera V.R., Neal D.D., Baden D.G., Messer S.A., Plakas S.M., et al. An electrochemiluminescence-based competitive displacement immunoassay for the type-2 brevetoxins in oyster extracts. J AOAC Int 2007, 90:173-178.
14. Ramos-Vara J.A. Technical aspects of immunohistochemistry. Vet Path 2005, 42:405-426.
15. Taga T., Kawanishi Y., Hardy R.R., Hirano T., Kishimoto T. Receptors for B cell stimulatory factor 2, quantitation, specificity, distribution, and regulation of their expression. J Exp Med 1987, 166:967-981.
16. Yoshio-Hoshino N., Adachi Y., Aoki C., Pereboev A., Curiel D.T., Nishimoto N. Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Res 2007, 67:871-875.